Abstract A015: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor
JAB-BX600 exhibits potent anti-tumor activity in KRAS G12D-mutant tumor models and a favorable preclinical safety profile, which support further clinical development of JAB-BX600 as a promising therapeutic strategy for KRAS G12D-driven cancers, particularly CRC and PDAC.